Discover & Learn
-
- 16/12/2024
AlF-peptides labelling method - One process to label them all…-
Publication
-
Nuclear Medicine
Simplified preparation. Better controlled dilution (critical step). Standard size vials. Efficient, fast and robust.
IBA intends to propose commercial kits for AlF-peptide process on Synthera®+ (IFP, reagents, ancillaries).
Precursor and final formulation are to be purchased by the customer and will not be provided by IBA. -
- 16/12/2024
[18F]FES /16α-[18F]-fluoroestradiol-
Publication
-
Oncology
Radiolabeled analog of estradiol is used as a PET imaging probe for estrogen receptor-positive breast cancer lesions.
To ensure that the obtained product meets quality control requirements for drug release we decided to use high pressure liquid chromatography purification (HPLC).
-
- 16/12/2024
18F-flotufolastat (previously known as 18F rhPSMA-7.3)-
Publication
-
End-to-end Lifecycle
Flotufolastat (previously known as 18F rhPSMA-7.3) developed by Blue Earth Diagnostics stands out as a promising theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) receptor. Diagnostic 18F-flotufolastat enables high-resolution PET imaging of PSMA-expressing lesions. Its favorable positron energy and longer half-life (109.8 minutes – comparing to 68Ga-labeled compounds) enhance image quality and sensitivity.
Approved by the FDA for commercial use.
It can also be labeled with therapeutic radiometals (such as 177Lu and 225Ac) for targeted radiotherapy. The dual-labeling capability opens avenues for targeted radiotherapy, potentially improving treatment outcomes. -
- 06/08/2024
Improved Production of Novel Radioisotopes with Custom Energy Cyclone® KIUBE-
Publication
-
End-to-end Lifecycle
The paper highlights the unique capabilities of the IBA Cyclone® KIUBE, particularly its variable energy feature. The application of this feature was demonstrated through hundreds of routine production runs of the 68Ga-liquid target with improved radionuclidic purity, longer shelf-life, and higher activity levels.
-
- 06/02/2024
Al[18F]F-NOTA-Octreotide & [68Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumors in Latin America-
Publication
-
End-to-end Lifecycle
In the present work we investigated the clinical utility of Al[18F]F-NOTAOctreotide (Al[18F]F-OC) in comparison to [68Ga]Ga-DOTA-TATE in patients diagnosed with neuroendocrine tumours. Our aim was to verify the recently published, promising results for Al[18F]FNOTA-Octreotide in the Latin-American population. Al[18F]F-NOTA-Octreotide provided excellent image quality, detected NET lesions with high sensitivity and represents a highly promising, clinical alternative to [68Ga]Ga-DOTA-TATE.